The accompanying editorial in the NEJM is interesting too. "... the therapeutic gain, with the rates of response to treatment (i.e., adequate relief) ranging between 9 and 12% more with rifaximin than with placebo, is in the lower spectrum of what is considered to be clinically relevant."
And neither rifaximin nor any other antibiotic has been approved for the treatment of IBS by the FDA. The study only addressed IBS-D not IBS-C. It will be interesting to see what the FDA decides in March.
-------------------- STABLE: ♂, IBS-D 50+ years - Science of IBS
Posts
Re: New Xifaxan 550 Study - Approval Date for IBS-D 3/7/2011
